Assessing Novavax (NVAX) Valuation After Recent Share Price Swings And Royalty Deal Outlook

Novavax: recent performance snapshot for retail investors

Novavax (NVAX) has drawn attention after recent share price swings, with the stock closing at US$7.97 and showing mixed returns over the past month and past 3 months.

For context, the company reports annual revenue of US$1.12b from recombinant vaccines, including its commercialized COVID-19 product Nuvaxovid and the R21 Matrix-M adjuvant malaria vaccine.

See our latest analysis for Novavax.

The recent 1 day share price return of 3.51% comes after a 30 day share price decline of 20.14%. The 1 year total shareholder return of 21.87% contrasts with a 5 year total shareholder return decline of 95.46%, which points to improving momentum in the shorter term but a challenging longer term record.

If you are comparing Novavax with other healthcare names using AI and data driven tools, it can be helpful to scan a wider peer set through 37 healthcare AI stocks

With Novavax trading at US$7.97 and sitting at an estimated 73% discount to analyst price targets and an implied intrinsic discount of 81%, investors need to consider whether this is a genuine mispricing or whether the market is already factoring in its future potential.

Most Popular Narrative: 42.2% Undervalued

With Novavax last closing at $7.97 and the most followed narrative pointing to a fair value of $13.78, the gap between price and modeled value is wide and rooted in specific assumptions about its vaccine platform and licensing deals.

The license agreement with Pfizer, including a US$30m upfront payment and high mid single digit royalties on products containing Matrix M, adds a defined cash inflow and a potential recurring royalty stream that can support enterprise value beyond the core COVID vaccine business.

Read the complete narrative. Read the complete narrative.

Curious what underpins that fair value gap? The narrative leans heavily on future margins, partner driven royalty flows, and a very punchy earnings multiple. The real surprise is how much of the valuation hangs on a few key revenue and profitability swing factors that are not obvious from recent share price moves.

Result: Fair Value of $13.78 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that fair value gap can close quickly if partner milestones slip or if COVID and combo vaccine demand falls short of the assumptions behind the royalty streams.

Find out about the key risks to this Novavax narrative.

Next Steps

Given the mix of long term share price pressure and a recent optimism driven narrative, it makes sense to look at the underlying data yourself and decide where you stand. Then weigh up the 3 key rewards and 5 important warning signs.

Ready to hunt for more investment ideas?

If Novavax has your attention, do not stop here. Broaden your watchlist now or you risk overlooking other compelling setups waiting in plain sight.

• Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations through the 62 high quality undervalued stocks.
• Explore potential income ideas by checking out companies screened for solid payouts and higher yields using the 13 dividend fortresses.
• Reduce the risk of downside surprises by focusing on companies with sturdier finances and cleaner balance sheets through the solid balance sheet and fundamentals stocks screener (40 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com